patient
FDA Approval of PiaSky for Pediatric Patients with PNH, Featuring Satheesh Chonat, MD
Dr. Satheesh Chonat explains how pediatric patients with PNH, or Paroxysmal Nocturnal Hemoglobinuria, may be treated with PiaSky in this recording. Listen now or read transcript below.
FDA Approval of PiaSky for Patients with PNH
Dr. Carlos DeCastro reviews how PiaSky can be used to treat patients with PNH, or Paroxysmal Nocturnal Hemoglobinuria. Listen or read the transcript below.
Jason Farrar, MD
Farrar, Jason
Pediatric Hematologist/Oncologist
Arkansas Children’s Hospital
Online Profile:
Nutrition and Bone Marrow Failure
Low-Risk MDS
In this webinar, Dr. Andrew Matthews discusses Low Risk MDS, current treatments and what's on the treatment horizon. Dr. Matthews took many questions from the live audience.
Ashwin Kishtagari, MD
Kishtagari, Ashwin
Hematologist Oncologist
Vanderbilt University Medical Center
Online Profile:
David Hermel, MD
Hermel, David
Hematologist Oncologist
Scripps Clinic
David Hermel, MD, is a hematologist and medical oncologist who specializes in malignant hematology with an interest in the use of novel therapies, such as cellular immunotherapy and
Online Profile:
Rory Shallis Explains New Therapy for Patients with Low-Risk MDS, Imetelstat
Dr. Rory Shallis explains the treatment, Imetelstat, for patients with Low Risk MDS. Listen or read the transcript below.
NMDP and CIBMTR share new, promising stem cell transplantation trial data using mismatched, unrelated donors at the 2024 EHA Congress
MINNEAPOLIS, June 14, 2024 — NMDPSM, a global nonprofit leader in cell therapy, and the CIBMTR® (Center for International Blood and Marrow Transplant Research®) announced interim results from the ACCESS trial as an oral abstract during the European Hematology Association (EHA) Annual Meeting in Madrid, Spain.